Moreover, a neutralizing anti-NGF antibody, successfully employed in chronic inflammation and preclinical models of PC [91], might be used in combination with abiraterone or enzalutamide to inhibit both neurotrophic growth factor as well as AR signaling. This evidence concerns the gene AR and pachyonychia congenita.